268 related articles for article (PubMed ID: 32492939)
1. Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review.
Pellat A; Coriat R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492939
[TBL] [Abstract][Full Text] [Related]
2. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Carcinomas of the Digestive Tract: What Is New?
Pellat A; Cottereau AS; Terris B; Coriat R
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359666
[TBL] [Abstract][Full Text] [Related]
4. Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions.
Pellat A; Cottereau AS; Palmieri LJ; Soyer P; Marchese U; Brezault C; Coriat R
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34070035
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
6. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
7. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
[TBL] [Abstract][Full Text] [Related]
8. [Consensus and controversy on subtype classification of gastric neuroendocrine neoplasms].
Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):977-981. PubMed ID: 28900986
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of primary site and pathology on 903 patients with neuroendocrine neoplasms].
Qiu X; Liu M; Liu Q; Yang Z; Liu J; Meng F; Wang Z; Shi Y; Liu L; Zhang P; Luo J; Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):993-996. PubMed ID: 28900988
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD133 in neuroendocrine neoplasms of the digestive tract: a detailed immunohistochemical analysis.
Mia-Jan K; Munkhdelger J; Lee MR; Ji SY; Kang TY; Choi E; Cho MY
Tohoku J Exp Med; 2013 Apr; 229(4):301-9. PubMed ID: 23615455
[TBL] [Abstract][Full Text] [Related]
12. Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors.
Sonbol MB; Halfdanarson TR
Curr Treat Options Oncol; 2019 Aug; 20(9):74. PubMed ID: 31428952
[TBL] [Abstract][Full Text] [Related]
13. Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors.
Cho CM
Korean J Gastroenterol; 2019 Mar; 73(3):124-131. PubMed ID: 31013555
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications.
Klöppel G
Visc Med; 2017 Oct; 33(5):324-330. PubMed ID: 29177160
[TBL] [Abstract][Full Text] [Related]
16. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
17. Early Gastroenteropancreatic Neuroendocrine Tumors: Endoscopic Therapy and Surveillance.
Scherübl H; Cadiot G
Visc Med; 2017 Oct; 33(5):332-338. PubMed ID: 29177161
[TBL] [Abstract][Full Text] [Related]
18. [Surgical treatment of gastric neuroendocrine neoplasms].
Wang W; Zhou ZW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Oct; 24(10):849-853. PubMed ID: 34674458
[TBL] [Abstract][Full Text] [Related]
19. Grade 3 well-differentiated neuroendocrine tumor of the rectum: a case report.
Ito M; Hirano Y; Isii T; Kondo H; Wang L; Asari M; Obara N; Yamaguchi S
Surg Case Rep; 2020 Jun; 6(1):130. PubMed ID: 32533349
[TBL] [Abstract][Full Text] [Related]
20. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
